A Comparison of Two Brief Suicide Prevention Interventions Tailored for Youth on the Autism Spectrum
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · May 25, 2022
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different suicide prevention strategies specifically designed for young people on the autism spectrum. The goal is to see which approach—either a Safety Planning Intervention tailored for autistic individuals (SPI-A) or the same intervention with added follow-up support (SPI-A+)—is more effective, feasible, and acceptable for helping these youth who might be at risk for suicide. This research is important because young people with autism are at a higher risk for suicidal thoughts and behaviors, and finding the best ways to support them is a priority.
To participate in the trial, you need to be between 12 and 24 years old, able to understand and speak English, and have already received a safety plan during a clinical visit. If you're under 18, you'll need permission from a parent or guardian. Participants can expect to engage in one of the two intervention strategies and have their experiences evaluated to help improve future suicide prevention efforts for autistic youth. The trial is currently recruiting participants, and both clinicians and health system leaders involved in the care of autistic youths can also take part in the study. Your involvement could help shape better support for young people facing these challenges.
Gender
ALL
Eligibility criteria
- • Patient Participants
- Inclusion Criteria:
- • 12-24 years old
- • Able and willing to provide informed consent (age ≥18) or assent and parental consent (age \<18)
- • Able to speak English
- • Have received a safety plan tailored for autistic youth during a clinical visit
- Exclusion Criteria:
- • Altered mental status that precludes ability to provide informed assent or consent (acute psychosis, intoxication, or mania)
- • Clinician Participants
- Inclusion Criteria:
- • Employment as a provider serving autistic patients at one of the study sites
- • Employment in a role that involves suicide risk intervention with youth patients at a participating clinic
- • Able to read and speak English
- • Able and willing to provide informed consent
- • 18-99 years old
- Exclusion Criteria:
- • There are no exclusion criteria for the clinician participants
- • Health System Leader Participants
- Inclusion Criteria:
- • Health system or clinic leader at one of the study sites
- • Employed in a role that provides administrative oversight to clinicians conducting safety plans with patients
- • Able to read and speak English
- • Able and willing to provide informed consent
- • 18-99 years old
- Exclusion Criteria:
- • There are no exclusion criteria for the health system leader participants
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Columbus, Ohio, United States
Seattle, Washington, United States
Chapel Hill, North Carolina, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Danielle Roubinov, PhD
Principal Investigator
University of North Carolina, Chapel Hill
Shari Jager-Hyman, PhD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials